Your search returned 3 studies. (Get alerts for new studies):
- Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
Conditions: B-Cell Lymphoma
1 Location available
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Conditions: NHL - Lymphoma, Non-Hodgkin - Lymphoma, B-Cell - Lymphoma, Follicular - Lymphoma, Intermediate-Grade - Lymphoma, Large-Cell - Lymphoma, Low-Grade - Lymphoma, Mixed-Cell - Lymphoma, Small-Cell - Leukemia, Lymphocytic, Chronic - Leukemia, B-Cell, Chronic -
4 Locations available
- Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Diffuse Mixed Cell Lymphoma - Recurrent Adult Diffuse Small Cleaved Cell Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
|